

Daiichi Sankyo sells Its Nihonbashi building in Japan

26 April 2019 | News

As part of Daiichi Sankyo's efforts toward the realization of its Vision for 2025 of being a "Global Pharma Innovator with competitive advantage in oncology", the company is prioritizing resource allocation to the oncology therapeutic area



Daiichi Sankyo Company LTD. (Daiichi Sankyo), dedicated to the creation and supply of innovative pharmaceutical products, announced that it has sold its wholly owned Nihonbashi Building located at Nihonbashi 3-chome, Chuo-ku, Tokyo, Japan.

As part of Daiichi Sankyo's efforts toward the realization of its Vision for 2025 of being a "Global Pharma Innovator with competitive advantage in oncology", the company is prioritizing resource allocation to the oncology therapeutic area. "Reinforcing profit generation capability" has been determined as a strategy for achieving this Vision, and the Nihonbashi Building was sold based on a policy of producing cash from non-core assets. Following the sale, Daiichi Sankyo will lease the building back from buyer and continue its current business activities there.

A profit of approximately ¥10.6 billion (before tax) will be recorded for the first quarter of fiscal 2019 on the sale of the Nihonbashi Building. However, at the request of the buyer, Daiichi Sankyo is not disclosing the buyer's name nor the amount of the sale.